A New Frontier for Neuromuscular Medicine
For Novartis, this isn’t just an acquisition — it’s a declaration of intent. The company’s foray into RNA therapeutics mirrors a broader industry trend, as pharmaceutical giants race to acquire biotech firms with promising platforms that bridge precision biology and data-driven drug design.
By integrating Avidity’s technology and expertise, Novartis aims to accelerate the development of RNA-based treatments capable of targeting diseases at their molecular roots — turning what once seemed impossible into scientific reality.
As Narasimhan put it, this deal “represents a powerful convergence of innovation, purpose, and potential — exactly what modern medicine needs.”
